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Introduction
In the intensive care unit (ICU) the need for acute renal
replacement therapy (aRRT) is associated with high mortal-
ity and risk of end-stage renal disease (ESRD). We investi-
gated long term mortality and progression to ESRD in ICU
patients requiring aRRT and factors associated to these.
Methods
Retrospective analysis of all adult patients admitted to
the general ICU, Rigshospitalet, from 1/1-2005 to 31/12-
2012, identified through the ICU database, excluding
chronic dialysis patients. ESRD was defined as the need
of dialysis >90 days or kidney transplant.
Results
Of 5766 patients included, 931 (16%) received aRRT,
4762 (83%) did not receive any RRT and 73 (1%) only
received aRRT during a later ICU admission. The 90-
day mortality was 55% for aRRT patients and 22% for
those not requiring aRRT (p < 0.001). The median
(IQR) age was 61 (49 - 68) for aRRT 90-day survivors
and 65 (55 - 73) for aRRT non-survivors (p < 0.001).
The median SAPS II score was 53 (43 - 64) for aRRT
90-day survivors and 61 (49 - 74) for aRRT non-survi-
vors (p < 0.001). Characteristics of aRRT patients devel-
oping ESRD and those that did not, are displayed in
tables 1-3. The 7-year risk of ESRD for patients surviv-
ing 90 days after admission was 10% (7 - 14) for aRRT
patients as compared to 0.5% (95% CI 0.3-0.9) for those
not receiving aRRT (p < 0.001).
Conclusions
The aRRT patients surviving 90 days were younger and
less severely ill at ICU admission as compared to the
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Table 1 Baseline characteristics
Data
available
90 day survivors with ESRD
(N = 38)
90 day survivors without ESRD
(N = 404)
P
Age (years), median (IQR) 442 61 (52.0 - 70.0) 61 (49 - 68) 0.400
Gender (male) 442 25 (65.8%) 271 (67.1%) 0.999
Days in the ICU, median (IQR) 442 7.2 (3.6 - 15.6) 10.9 (5.7 -
20.9)
0.087
SAPS II score (points), median
(IQR)
427 56 (41 - 68) 53 (43 - 64) 0.39
APACHE II score (points), median
(IQR)
427 30 (25 - 35) 26 (21 - 31) 0.009
First SOFA (points), median (IQR) 417 11 (8 - 15) 12 (9 - 14) 0.861
MAX SOFA (points), median (IQR) 418 12 (9 - 15) 13 (11 - 16) 0.377
Vasopressor treatment 442 24 (63.2%) 297 (73.5%) 0.279
Mechanical ventilation 442 30 (78.9%) 371 (91.8%) 0.040
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non-survivors. The survivors developing ESRD had more
frequently preexisting chronic kidney disease and higher
APACHE II scores as compared to those who did not
develop ESRD. aRRT patients had increased risk of
ESRD up to 7 years after ICU admission, emphasizing
the KDIGO recommendations to follow up AKI patients
due to their increased risk for CKD.
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Table 2. Preexisting Comorbidity
Data
available
90 day survivors with ESRD
(N = 38)
90 day survivors without ESRD
(N = 404)
P
Chronic kidney disease (non-
dialysis)
442 23 (60.5%) 90 (22.3%) <
0.001
Hypertension 442 14 (36.8%) 119 (29.5%) 0.505
Diabetes 442 6 (15.8%) 56 (13.9%) 0.784
Congestive heart failure 442 4 (10.5%) 39 (9.7%) 0.993
Peripheral vascular disease 442 9 (23.7%) 82 (20.3%) 0.734
Cerebrovascular disease 442 3 (7.9%) 36 (8.9%) 0.968
Malignant neoplasm 442 12 (31.6%) 83 (20.5%) 0.180
Ischemic heart disease 442 4 (10.5%) 29 (7.2%) 0.783
Chronic obstructive pulmonary
disease
442 4 (10.5%) 50 (12.4%) 0.928
Table 3. Primary diagnosis during ICU stay
Data
available
90 day survivors with ESRD
(N = 38)
90 day survivors without ESRD
(N = 404)
P
Sepsis 442 7 (18.4%) 112 (27.7%) 0.466
Other infectious diseases 442 6 (15.8%) 20 (5.0%) 0.025
Endocrinological diseases 442 (0.0%) 3 (0.7%) 0.868
Cardiovascular diseases 442 3 (7.9%) 43 (10.6%) 0.869
Respiratory diseases 442 9 (23.7%) 66 (16.3%) 0.514
Gastrointestinal or liver
diseases
442 2 (5.3%) 11 (2.7%) 0.675
Trauma or poisoning 442 4 (10.5%) 38 (9.4%) 0.975
Other 442 7 (18.4%) 111 (27.4%) 0.483
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